VA Pharmacy Benefits Management Strategic Healthcare Group Update




Joseph J. Canzolino, R.Ph. Associate Chief Consultant Pharmacy Benefits Management Strategic Healthcare Group Hines, IL

www.vapbm.org

vaww.pbm.med.va.gov

PURCHASING METHODS USED BY VA

VA Healthcare System
Effects Of Contracting
PPV Contract
Industry Access Policy
Cost Avoidance




- 172 hospitals
- 800 outpatient clinics
- 135 nursing homes
- 43 residential care facilities
- 206 readjustment counseling centers
- 73 home care programs
- 40,000 beds



Medical Care Staffing


FY 1994-2003



All Other * Other Health Care Providers Nurses Physicians & Dentists

* All Other includes Administrative, IT and Wage Board FTE

Growth in VHA Rx Workload FYs 1999-2002



SELECTED VHA STATISTICS: FY 2002-FY 2003

			YR TO YR
	FY 2002	FY 2003	CHANGE
Total Enrollees	6,788,781	7,120,347	4.9%
Total Patients Treated (uniques)	4,471,951	4,733,166	5.8%
Inpatient Admissions	565,565		
Outpatient Visits (includes fee visits)	46,452,859	49,800,357	7.2%

- Approx. 7M patients enrolled
- Approx. 5M active patients
- Approx. 4M pharmacy beneficiaries (FY 2003)

- 108,000,000 actual RXs in FY 2003
- 200,000,000 30-day equivalent RXs in FY 2003
- 3.1 Billion in PV drug costs in FY 2003

Workload FY 2003:

Facility 46,814,419 30 day eq. Rx 23%
 CMOP 153,207,098 30 day eq. Rx 77%



VA Pharmacy Service FY 2003

Prescriptions Workload	108 million
Co-payment per 30 day prescription*	\$7
Uniques Pharmacy Outpatients	4.0 million
Pharmacist FTE	5,148
Pharmacy Technicians	3,262
Outpatient Drug Cost	2.8 billion

In general, applied to prescriptions for non-service connected conditions, P 2-8


PBM Statistics

MEASURE	2003	Annual % Change
Avg. Rx Cost per Unique (PMPY)	\$705	6.3%
Avg. Rx Cost	\$26.13	9.8%
Avg. Rxs per Unique	27	-3.5%
Percent Formulary (by volume)	98%	0
Percent Formulary (by cost)	94%	1%


PBM Performance Monitors

MEASURE	2003	Prior Year
Avg.Drug Cost per Unique per Year	\$705	\$664
Percent CMOP	72%	70%
Percent Multimonth	44%	43%
Brand to Generic (%)	37 / 63	34 / 63
Legend to OTC	88 / 12	85 / 15


Type of Prescriptions FY 2003




30-day Equivalent Rxs



"OTC" 30-day Equivalent Rxs




Pharmacy Unique Users




Contracting Results

What are the effects of contracting on price and utilization?


Statin 30-day Equivalent Rxs




Average Cost per Unit for Statins




Non-Sedating Antihistamine 30day Equivalent Rxs



Average Cost per Unit for Non-Sedating Antihistamines




PPI 30-day Equivalent Rxs




Average Cost per Unit for PPIs




DRUG DISPENSING TRENDS



DRUG DISPENSING TRENDS



Utilization Management 30-Day Equiv RXs / All RXs for COX-IIs




PHARMACEUTICAL PRIME VENDOR CONTRACT

PARTNERSHIP

- Distribute pharmaceutical and medical/surgical supplies to VA, IHS, BOP, CMOPs, State Veterans Homes
- Electronic order entry
- Next day delivery
- 97% fill rate
- Accurate product pricing and invoicing
- Negative Five Percent (-5%) distribution fee


PHARMACEUTICAL PRIME VENDOR SALES



PURCHASING METHODS USED BY VA

Federal Supply Schedule (FSS)
Blanket Purchase Agreement (BPA)
National Contracts
Basic Ordering Agreement (BOA)
Open Market Purchase

IA SALES



RECAP/GOALS

- Decrease open market purchases
- Minimize back-orders
- Review rebates on BPAs
- High quality products at low prices (standardization)
- Pharmaceutical Prime Vendor implementation
- Medical/Surgical Prime Vendor
- Repackaging
- Equipment and automation

NATIONAL POLICY ON MANUFACTURER'S REPRESENTATIVES

MANUFACTURER'S POLICY

Purpose is to establish clear, consistent and uniform rules governing product manufacturer's activities within the Department

- 1st draft completed in August 2002
- Conference call with industry representatives September 16th, 2002
- Meeting with VA and industry representatives for October 4th to develop 2nd draft
- VA Office of General Counsel comments incorporated and sent to VAHQ March 2003
- 10th draft will be reviewed by VA Health Systems Council in May 2003.
- Final draft will be put into the concurrence process in VAHQ in June 2003
- Directive will be issued.....? (July 2003?)

MANUFACTURER'S POLICY

Possible Final Policy Elements:

Consideration of VA staff time constraints

Guidance on drug samples / gifts

Promotional materials / literature

Product promotion consistent with the VANF goals


Patient privacy

Policy non-compliance

Tools Used to Achieve Cost Avoidance

- <u>Utilization Management</u> Pharmacologic Management Guidelines :
 - PBM-MAP
 - PBM-MAP Drug Use Criteria
 - Formulary Design (generics, formulary status)
- <u>Contracting:</u>
 - Public Law 102-585 (24% off Non-Federal Average Manufacturer Prices)
 - FSS (prices negotiated below Federal Ceiling Price)
 - Blanket Purchasing Agreements (additional 5 to 15% off FSS)
 - National Contracts (additional 10 to 60% off FSS)
- Distribution Systems
 - Pharmacy Inventory Management
 - Pharmaceutical Prime Vendor (3 to 4% discount off contract price)
 - CMOP Dispensing


Annual Cost Avoidance



* Based on 1st & 2nd QTR FY 2003 data and pending contract awards. Cost avoidance calculation methodology endorsed by GAO health economist and management staff representatives

Cumulative Cost Avoidance

National Contract Cost Avoidance History



Fiscal Year

FY 1996 through FY 2003 estimated cost avoidance is <u>\$1,681,452,985</u> (Cost Avoidance = Theoretical Cost – Actual Cost)

FILLING RXs WRITTEN BY NON-VA PROVIDERS

NON VA RXs

Four draft Bills in the U.S. House of Representatives

- HR 240 (Mica)
- HR 372 (Lynch)
- HR 709 (Wicker)
- HR 1309 9Evans)

Requirements, financial impact, and impact on VA pharmacy capacity vary across all Bills

